Fig. 6

March1 is required for dampened alloreactivity induced by DnaK. Skin allografts from WT or March1^−/− mice (both H-2K^b/I-A^b) were treated with DnaK or control and transplanted into BALB/c (H-2K^d/I-A^d) recipients. a Gating strategy for tracking donor MHC II (I-A^b) in cross-dressed host CD103⁺ DCs. b Donor MHC II (I-A^b) and c CD86 levels in cross-dressed host CD103⁺ DCs graft dLN at day 1 and 4 post-transplant. d Percent of allograft survival. Statistics using log-rank test (n = 5/group). e Numbers of CD4⁺Ki67⁺ and CD8⁺Ki67⁺ T cells, and f CD4⁺ and CD8⁺ TEM cells from allograft dLNs harvested at day 1 and 4 post-transplant. Statistics using ANOVA with Tukey post-test. n = 3 mice per group. Bar graphs represent the mean ± S.D. g WT or March1^−/− BMDCs were treated with DnaK for 24 h, irradiated and cultured with allogeneic T cells for 24 h in mouse IFN-γ-coated plates. IFN-γ production by T cells was measured by ELISPOT. Numbers of spots per million T cells ± S.D. in triplicates. Statistics using ANOVA with Tukey post-test. Representative results of at least two independent experiments